10-Year biochemical (prostate-specific antigen) control of prostate cancer with 125I brachytherapy

International Journal of Radiation Oncology Biology Physics

Volumn 51, Issue 1, 2001, Pages 31-40

  Grimm, Peter D ^a,c   Blasko, John C ^a   Sylvester, John E ^a,b   Meier, Robert M ^a   Cavanagh, William ^a  

^a SWEDISH MEDICAL CENTER   (United States)

^b Puget Sound Tumor Institute   (United States)

^c Seattle Prostate Institute   (United States)

Author keywords

Brachytherapy; Prostate cancer; Prostate specific antigen; Radiotherapy

Indexed keywords

BODY FLUIDS; IODINE; PATIENT TREATMENT; RADIOISOTOPES; TUMORS;

BRACHYTHERAPY;

ONCOLOGY;

IODINE 125; ISOTOPE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BRACHYTHERAPY; CANCER STAGING; CONTROLLED STUDY; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROSTATE CARCINOMA; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

AGED; BRACHYTHERAPY; CONFIDENCE INTERVALS; CROSS-SECTIONAL STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASM STAGING; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TIME FACTORS; TREATMENT FAILURE;

EID: 0035450305     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(01)01601-7     Document Type: Article

References (13)

1. Ultrasound-guided transperineal implantation of Iodine-125 and Palladium-103 for the treatment of early-stage prostate cancer: Technical concepts in planning, operative technique, and evaluation
2. Guidelines for PSA following radiation therapy
3. Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer
4. Transient elevation of serum prostate-specific antigen following 125I/103Pd brachytherapy for localized prostate cancer
5. Prostate specific antigen bounce after radioactive seed implantation followed by external beam radiation for prostate cancer
6. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings
7. The pathologist as optimist: Cancer grade deflation in prostatic needle biopsies
8. Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques
9. Modern prostate brachytherapy. Prostate specific antigen results in 219 patients with up to 12 years of observed follow-up
10. Palladium-103 brachytherapy for prostate carcinoma
11. Comparison of the 5-year outcome and morbidity of three-dimensional conformal radiotherapy versus transperineal permanent iodine-125 implantation for early-stage prostatic cancer
12. Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer